Manufacturer
RANBAXY (MALAYSIA) SDN. BHD.
Contents
Levofloxacin
Indication
Acute bacterial sinusitis, Community-acquired pneumonia, Complicated skin and soft tissue infections, Chronic bacterial prostatitis, Acute bacterial exacerbation of chronic bronchitis, Pyelonephritis, Treatment and postexposure prophylaxis of inhalation anthrax, Uncomplicated cystitis, Complicated urinary tract infections.
Instruction
May be taken with or without food. Ensure adequate fluid intake.
Drug interaction
Decreased absorption with Fe salts, Zn-containing multivitamins, Mg- or Al-containing antacids, didanosine. Decreased bioavailability with sucralfate. Increased risk of CNS stimulation and seizures with drugs which may affect seizure threshold (e.g. theophylline, NSAIDs). Decreased renal clearance with cimetidine and probenecid due to blockage of renal tubular secretion of levofloxacin. May increase the half-life of ciclosporin. Increased INR and/or bleeding with vitamin K antagonists (e.g. warfarin). Increased risk of severe tendon disorders with corticosteroids. Increased risk for QT interval prolongation with class IA and III antiarrhythmics, TCA, macrolides and antipsychotic agents. May result to altered blood glucose levels with antidiabetic agents (e.g. insulin, glibenclamide).
Malaysia
